What is Interline Therapeutics?
Based in San Francisco, Interline Therapeutics operates at the vanguard of precision medicine. The company specializes in the systematic elucidation of protein communities, a methodology designed to define the molecular mechanisms underlying human disease. By moving beyond traditional single-target drug discovery, Interline aims to decode the intricate biological networks that drive pathology. This systemic perspective allows the organization to identify novel intervention points, positioning it as a critical player in the next generation of pharmaceutical innovation. The firm's focus on high-resolution biological mapping provides a competitive edge in developing targeted therapies for complex conditions that have historically eluded conventional research models.
How much funding has Interline Therapeutics raised?
Interline Therapeutics has raised a total of $92M across 1 funding round:
Other Financing Round
$92M
Other Financing Round (2021): $92M with participation from Foresite Capital and ARCH Venture Partners
Key Investors in Interline Therapeutics
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists.
What's next for Interline Therapeutics?
The recent infusion of capital is earmarked for the expansion of Interline's research infrastructure and the acceleration of its lead pipeline programs. As the company transitions into a more mature phase of development, the focus will shift toward validating its protein-community insights through clinical-stage milestones. By leveraging its robust balance sheet, Interline is well-positioned to scale its computational biology capabilities and forge strategic partnerships that enhance its drug development velocity. The firm remains committed to its core mission of transforming disease management through a deeper, data-driven understanding of cellular architecture, ensuring that its scientific advancements translate into tangible clinical outcomes for patients with significant unmet medical needs.
See full Interline Therapeutics company page
